Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Prospective Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp

NCT07309822 is registered in ClinicalTrials.gov with Probelte Pharma S.L.U. as lead sponsor.

NCT NCT07309822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07309822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Prospective Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp
Lead sponsor
Probelte Pharma S.L.U.
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2025
Completion date
December 31, 2031
Enrollment
27 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

allergy